AzTrials
AzTrials

Weight LossPhase 3VANQUISH 1NCT07104500

VK2735 for Weight Management Phase 3

A Phase 3 study testing VK2735 in people with Weight Loss, run by Viking Therapeutics, Inc. at 137 sites in 2 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Weight Loss
What is being tested?
VK2735
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
4,500 participants
Where
137 sitesin 2 countries
Study dates
23 Jun 2025to 1 Aug 2027
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years of age at the time of signing the informed consent
  • Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co- morbid condition (treated or untreated)
  • Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease
  • Cardiovascular disease includes, for example, ischemic cardiovascular disease, New York Heart Association (NYHA) Functional Class I-III heart failure
  • BMI calculated at the Screening visit will be used to determine eligibility

Who cannot join

  • History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
  • Self-reported body weight change of 5% or more within 3 months of screening
  • Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed >1 year prior to screening)
  • Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as, mucosa ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
  • Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes)
  • Treatment with glucose-lowering agent(s) within 90 days before screening
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
  • History of acute or chronic pancreatitis

Trial locations and contacts

137 sites in 2 countries.

137 sites in 2 countries

United States135 sites

  • Viking Clinical Site #1047

    Abilene, Texas, 79606

  • Viking Clinical Site #1088

    Albany, New York, 12205

  • Viking Clinical Site #1029

    Albuquerque, New Mexico, 87109

  • Viking Clinical Site #1098

    Arlington, Virginia, 22205

  • Viking Clinical Site #1116

    Atlanta, Georgia, 30329

  • Viking Clinical Site #1063

    Austin, Texas, 78131

  • Viking Clinical Site #1007

    Austin, Texas, 78705

  • Viking Clinical Site #1118

    Baton Rouge, Louisiana, 70808

  • Viking Clinical Site #1139

    Baton Rouge, Louisiana, 70809

  • Viking Clinical Site #1091

    Bellaire, Texas, 77401

  • Viking Clinical Site #1037

    Birmingham, Alabama, 35235

  • Viking Clinical Site #1064

    Birmingham, Alabama, 35249

  • Viking Clinical Site #1103

    Boston, Massachusetts, 02114

  • Viking Clinical Site #1124

    Brownsville, Texas, 78526

  • Viking Clinical Site #1010

    Butte, Montana, 59701

  • Viking Clinical Site #1005

    Chandler, Arizona, 85210

  • Viking Clinical Site #1141

    Charlotte, North Carolina, 28250

  • Viking Clinical Site #1094

    Chevy Chase, Maryland, 20815

  • Viking Clinical Site #1006

    Chicago, Illinois, 60607

  • Viking Clinical Site #1090

    Chicago, Illinois, 60640

  • Viking Clinical Site #1071

    Chula Vista, California, 91911

  • Viking Clinical Site #1043

    Cincinnati, Ohio, 45219

  • Viking Clinical Site #1074

    Cincinnati, Ohio, 45242

  • Viking Clinical Site #1031

    City of Saint Peters, Missouri, 63303

  • Viking Clinical Site #1013

    Clearwater, Florida, 33756

  • Viking Clinical Site #1121

    Clearwater, Florida, 33761

  • Viking Clinical Site #1044

    Cleveland, Ohio, 44122

  • Viking Clinical Site #1030

    Columbus, Georgia, 31904

  • Viking Clinical Site #1089

    Columbus, Ohio, 43215

  • Viking Clinical Site #1003

    Cooper City, Florida, 33024

  • Viking Clinical Site #1049

    Dallas, Texas, 75230

  • Viking Clinical Site #1048

    Dallas, Texas, 75235

  • Viking Clinical Site #1112

    DeLand, Florida, 32720

  • Viking Clinical Site #1107

    Delray Beach, Florida, 33445

  • Viking Clinical Site #1119

    Denver, Colorado, 80210

  • Viking Clinical Site #1122

    Durham, North Carolina, 27701

  • Viking Clinical Site #1045

    East Greenwich, Rhode Island, 02818

  • Viking Clinical Site #1042

    East Syracuse, New York, 13057

  • Viking Clinical Site #1070

    Escondido, California, 92025

  • Viking Clinical Site #1027

    Fargo, North Dakota, 58104

  • Viking Clinical Site #1144

    Fayetteville, North Carolina, 28304

  • Viking Clinical Site #1017

    Flagstaff, Arizona, 86001

  • Viking Clinical Site #1083

    Fort Myers, Florida, 33912

  • Viking Clinical Site #1111

    Frisco, Texas, 75033

  • Viking Clinical Site #1026

    Greensboro, North Carolina, 27410

  • Viking Clinical Site #1028

    Greenville, South Carolina, 29607

  • Viking Clinical Site #1140

    Gulfport, Mississippi, 39503

  • Viking Clinical Site #1096

    Hartsdale, New York, 10530

  • Viking Clinical Site #1062

    Honolulu, Hawaii, 96814

  • Viking Clinical Site #1046

    Houston, Texas, 77040

  • Viking Clinical Site #1054

    Huntington Park, California, 90255

  • Viking Clinical Site #1128

    Huntsville, Alabama, 35801

  • Viking Clinical Site #1058

    Jacksonville, Florida, 32216

  • Viking Clinical Site #1016

    Kansas City, Missouri, 64131

  • Viking Clinical Site #1004

    Knoxville, Tennessee, 37909

  • Viking Clinical Site #1106

    Lafayette, Louisiana, 70508

  • Viking Clinical Site #1014

    Lake Forest, California, 92630

  • Viking Clinical Site #1076

    Lakeland, Florida, 33803

  • Viking Clinical Site #1060

    Lakewood Rch, Florida, 34211

  • Viking Clinical Site #1077

    Lampasas, Texas, 76550

  • Viking Clinical Site #1035

    Las Vegas, Nevada, 89148

  • Viking Clinical Site #1065

    Lebanon, New Hampshire, 03756

  • Viking Clinical Site #1129

    Lemon Grove, California, 91945

  • Viking Clinical Site #1069

    Lexington, Kentucky, 40509

  • Viking Clinical Site #1040

    Lexington, Kentucky, 40513

  • Viking Clinical Site #1051

    Lincoln, California, 95648

  • Viking Clinical Site #1036

    Little Rock, Arkansas, 72211

  • Viking Clinical Site #1050

    Long Beach, California, 90815

  • Viking Clinical Site #1055

    Los Angeles, California, 90057

  • Viking Clinical Site #1009

    Louisville, Kentucky, 40213

  • Viking Clinical Site #1078

    Manteca, California, 95336

  • Viking Clinical Site #1095

    Marlton, New Jersey, 08009

  • Viking Clinical Site #1102

    Medford, Oregon, 97504

  • Viking Clinical Site #1080

    Meridian, Idaho, 83642

  • Viking Clinical Site #1020

    Metairie, Louisiana, 70006

  • Viking Clinical Site #1001

    Methuen, Massachusetts, 01844

  • Viking Clinical Site #1117

    Miami, Florida, 33122

  • Viking Clinical Site #1081

    Mobile, Alabama, 36608

  • Viking Clinical Site #1087

    Monroe, Louisiana, 71201

  • Viking Clinical Site #1053

    Montclair, California, 91763

  • Viking Clinical Site #1110

    Morehead City, North Carolina, 28557

  • Viking Clinical Site #1061

    Morehead City, North Carolina, 28857

  • Viking Clinical Site #1134

    Myrtle Beach, South Carolina, 29572

  • Viking Clinical Site #1008

    Nashville, Tennessee, 37203

  • Viking Clinical Site #1136

    Needham, Massachusetts, 02492

  • Viking Clinical Site #1059

    New Port Richey, Florida, 34652

  • Viking Clinical Site #1133

    New York, New York, 10036

  • Viking Clinical Site #1142

    New York, New York, 10065

  • Viking Clinical Site #1113

    Norman, Oklahoma, 73069

  • Viking Clinical Site #1023

    North Charleston, South Carolina, 29405

  • Viking Clinical Site #1012

    Ocoee, Florida, 34761

  • Viking Clinical Site #1002

    Ogden, Utah, 84405

  • Viking Clinical Site #1075

    Omaha, Nebraska, 68134

  • Viking Clinical Site #1056

    Palmetto Bay, Florida, 33157

  • Viking Clinical Site #1068

    Panorama City, California, 91402

  • Viking Clinical Site #1018

    Peoria, Arizona, 85381

  • Viking Clinical Site #1011

    Port Orange, Florida, 32127

  • Viking Clinical Site #1097

    Portland, Oregon, 97202

  • Viking Clinical Site #1126

    Portland, Oregon, 97210

  • Viking Clinical Site #1034

    Reno, Nevada, 89511

  • Viking Clinical Site #1072

    Renton, Washington, 98057

  • Viking Clinical Site #1120

    Rincon, Georgia, 31326

  • Viking Clinical Site #1066

    Rockville, Maryland, 20854

  • Viking Clinical Site #1132

    Rolling Hills Estates, California, 90274

  • Viking Clinical Site #1092

    Salt Lake City, Utah, 84107

  • Viking Clinical Site #1143

    San Antonio, Texas, 78215

  • Viking Clinical Site #1085

    San Antonio, Texas, 78222

  • Viking Clinical Site #1073

    San Antonio, Texas, 78229

  • Viking Clinical Site #1131

    San Diego, California, 92103

  • Viking Clinical Site #1039

    Sandy City, Utah, 84094

  • Viking Clinical Site #1104

    Santa Maria, California, 93458

  • Viking Clinical Site #1093

    Savannah, Georgia, 31406

  • Viking Clinical Site #1135

    Scottsdale, Arizona, 85260

  • Viking Clinical Site #1041

    Spokane, Washington, 99218

  • Viking Clinical Site #1052

    Spring Valley, California, 91978

  • Viking Clinical Site #1125

    Springfield, Missouri, 65807

  • Viking Clinical Site #1108

    St Louis, Missouri, 63108

  • Viking Clinical Site #1024

    St. George, Utah, 84790

  • Viking Clinical Site #1082

    Suffolk, Virginia, 23435

  • Viking Clinical Site #1021

    The Bronx, New York, 10455

  • Viking Clinical Site #1019

    Tucson, Arizona, 85711

  • Viking Clinical Site #1137

    Tulsa, Oklahoma, 74133

  • Viking Clinical Site #1109

    Tustin, California, 92780

  • Viking Clinical Site #1127

    Valparaiso, Indiana, 46383

  • Viking Clinical Site #1067

    Van Nuys, California, 91405

  • Viking Clinical Site #1101

    Waco, Texas, 76710

  • Viking Clinical Site #1079

    Walnut Creek, California, 94598

  • Viking Clinical Site #1123

    Washington D.C., District of Columbia, 20036

  • Viking Clinical Site #1022

    West Des Moines, Iowa, 50266

  • Viking Clinical Site #1057

    West Palm Beach, Florida, 33407

  • Viking Clinical Site #1032

    Westfield, New York, 14787

  • Viking Clinical Site #1138

    Westmont, Illinois, 60559

  • Viking Clinical Site #1099

    Wichita, Kansas, 67207

  • Viking Clinical Site #1025

    Woodstock, Georgia, 30189

  • Viking Clinical Site #1038

    Ypsilanti, Michigan, 48197

Other trials in United States

Puerto Rico2 sites

  • Viking Clinical Site #1130

    Mayagüez, 00680

  • Viking Clinical Site #1086

    San Juan, 00927

Other trials in Puerto Rico

About this study

Official title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.

Conditions
Weight Loss
Being tested
VK2735
Medical subject headings
Weight Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VK2735Drug

    VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly

Study groups in NCT07104500
Study groupRoleWhat they receive
Placebo AssignmentPlacebo comparatorVK2735 Placebo Comparator Once Weekly
Receives: Drug: VK2735
Active Assignment (Dose 1)ExperimentalVK2735 7.5mg Once Weekly
Receives: Drug: VK2735
Active Assignment (Dose 2)ExperimentalVK2735 12.5mg Once Weekly
Receives: Drug: VK2735
Active Assignment (Dose 3)ExperimentalVK2735 17.5mg Once Weekly
Receives: Drug: VK2735

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment

    Measured: 78 Weeks

Secondary outcomes (1)

  1. Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment

    Measured: 78 Weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Aug 2025
  2. Study start23 Jun 2025
  3. Primary completion1 Jul 2027 (estimated)
  4. Study completion1 Aug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
4,500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07104500
Sponsor's protocol ID
VK2735-301
Acronym
VANQUISH 1
Status last verified
Nov 2025
First submitted
29 Jul 2025
Last updated
24 Nov 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing VK2735 in people with Weight Loss, run by Viking Therapeutics, Inc. at 137 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 24 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 137 sites in United States, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment (time frame: 78 Weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07104500.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Nov 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in